1. Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment
- Author
-
Ga-Young Song, Sae-Ryung Kang, Cho Heejeong, Hee-Seung Bom, Hyeoung-Joon Kim, Sung-Hoon Jung, Jung-Joon Min, Deok-Hwan Yang, Chae Moon Hong, Hwa Kyung Park, Dong Won Baek, Shin Young Jeong, Jae-Sook Ahn, Joon Ho Moon, Sang Kyun Sohn, Je-Jung Lee, and Seo-Yeon Ahn
- Subjects
medicine.medical_specialty ,Prognostic factor ,Hematology ,Multivariate analysis ,medicine.diagnostic_test ,business.industry ,medicine.disease ,Normal renal function ,Positron emission tomography ,Internal medicine ,medicine ,Fdg pet ct ,In patient ,business ,Nuclear medicine ,Multiple myeloma - Abstract
Renal insufficiency (RI) is a frequent manifestation of multiple myeloma (MM) at time of diagnosis but there is no reliable prognostic factor for patients with MM presenting with RI. This study investigated the prognostic impact of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in patients with MM with RI at diagnosis. The records of 209 patients with MM between June 2011 and November 2018 were retrospectively analyzed. PET/CT positivity was defined as the presence of more than three focal lesions or the presence of extramedullary disease. Of 209 patients, 90 (43.1%) had RI and showed similar survival outcomes to patients who had normal renal function. In total, 113 patients (54.0%) were PET/CT-positive, and 46.6% of patients with RI were PET/CT-positive at baseline. In patients with RI, those who were PET/CT-positive showed significantly inferior survival outcomes to those who were PET/CT-negative [progression-free survival (PFS), 12.7 vs. 34.0 months, P
- Published
- 2021
- Full Text
- View/download PDF